What changed in Medpace Holdings, Inc.'s latest annual report
In the year ended 31 Dec 2025, Medpace Holdings, Inc.'s revenue rose 20% to USD 2.53bn, from USD 2.11bn; net income rose 11.6% to USD 451.12m, from USD 404.39m; shareholders' equity fell 44.4% to USD 459.07m, from USD 825.54m.
Year ended 31 Dec 2025. Source: 10-K filed 10 Feb 2026, read it on SEC EDGAR.
USD 2.11bn to USD 2.53bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.11bn | 2.53bn | Up 20% |
| Net income | 404.39m | 451.12m | Up 11.6% |
| Total assets | 2.10bn | 1.98bn | Down 6% |
| Total liabilities | 1.28bn | 1.52bn | Up 18.9% |
| Cash and cash equivalents | 669.44m | 497.05m | Down 25.8% |
| Shareholders' equity | 825.54m | 459.07m | Down 44.4% |
Questions people ask
Did Medpace Holdings, Inc.'s revenue grow last year?
Revenue grew 20%, from USD 2.11bn to USD 2.53bn in the year ended 31 Dec 2025.
Is Medpace Holdings, Inc. profitable?
Yes. Net income was USD 451.12m in the year ended 31 Dec 2025. The year before: USD 404.39m.
How much cash and debt does Medpace Holdings, Inc. have?
At its latest year end (31 Dec 2025), Medpace Holdings, Inc. reported cash and cash equivalents of USD 497.05m.
Where do these numbers come from?
From Medpace Holdings, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Medpace Holdings, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc.Cash and cash equivalents up 16.3%
- Incyte CorporationNet income up 3845%
- Charles River Laboratories International, Inc.Cash and cash equivalents up 9.8%
- ICON plcNet income down 69%